mirxes
Singapore’s biotech game needs a reset
The country has yet to produce a big pharma champion, but its biotech engine is heating up through licensing, talent, and steady clinical progress.
Tessa Oh · · 6 min read
From IP to IPO: How Mirxes’ IP strategy set it up for success
Knowledge is the most valuable asset for a biotech firm. Mirxes leveraged a variety of approaches to protect its expertise.
Stefanie Yeo · · 7 min read
Mirxes narrow losses as H1 revenue rises to $10.5m
Mirxes said it made progress in registering its GASTROClear test in China, expanding testing services in Japan.
Grace Priscilla Teo · · 2 min read
SEA firms test Hong Kong’s IPO comeback
After a lull, Southeast Asian firms are trickling back to HKEX. But while listing activity is rising, Wall Street and home markets still dominate their plans.
Evan See · · 5 min readHong Kong replaces Wall Street as China’s IPO hotspot
As US markets become virtually inaccessible to Chinese companies, Hong Kong emerges as the new IPO capital for firms like CATL and Mixue seeking overseas expansion.
Alec Tseung · · 5 min readMirxes becomes SEA’s first biotech unicorn after HK IPO
Mirxes specializes in miRNA technology and aims to enhance precision medicine solutions for Southeast Asia.
Naomi Li Gan · · 3 min readPharma giant Hengrui, Mirxes debut strong week for HK IPOs
Jiangsu Hengrui’s shares were oversubscribed 455 times, showcasing strong retail demand during its IPO.
Minh Le · · 3 min readMirxes to raise $112.7m in Hong Kong IPO
Shares will start trading on May 23, 2025, under stock code 2629.
Aiko Gao Ishida · · 3 min readMirxes secures $40m to expand cancer diagnostics in Asia
Mirxes created GastroClear, the first gastric cancer diagnostic test to gain global regulatory approval.
Naomi Li Gan · · 2 min readSingapore’s biotech sector is more successful than people think
Over 20 years in the making, buttressed by billions of dollars in public sector funding, Singapore’s biotech sector has been a magnet for scrutiny.
Melissa Goh · · 8 min read